Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide D (DV3396) vs Reference (PDS290) in Overweight/Obesity
NCT04238962Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2020
- Primary completion
- Oct 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in Overweight and obesity (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement and Maximum observed semaglutide concentration. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT04238962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238962.